Seroatlas · Human Serome Atlas

SPON2

Spondin-2

Also known as: DIL1, SPON2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9BUD6
Gene: SPON2
Ensembl: ENSG00000159674
Chromosome: 4
Canonical length: 331 aa
Protein class: Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Vesicles
Secretome location: Secreted to blood

OverviewNCBI Gene

Predicted to enable antigen binding activity; lipopolysaccharide binding activity; and metal ion binding activity. Predicted to be involved in cell adhesion. Predicted to act upstream of or within several processes, including defense response to other organism; opsonization; and positive regulation of cytokine production. Located in extracellular exosome. Biomarker of meningioma. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

331 residues, UniProt reviewed canonical sequence.

>Q9BUD6|SPON2
     1  MENPSPAAAL GKALCALLLA TLGAAGQPLG GESICSARAL AKYSITFTGK WSQTAFPKQY
    61  PLFRPPAQWS SLLGAAHSSD YSMWRKNQYV SNGLRDFAER GEAWALMKEI EAAGEALQSV
   121  HAVFSAPAVP SGTGQTSAEL EVQRRHSLVS FVVRIVPSPD WFVGVDSLDL CDGDRWREQA
   181  ALDLYPYDAG TDSGFTFSSP NFATIPQDTV TEITSSSPSH PANSFYYPRL KALPPIARVT
   241  LVRLRQSPRA FIPPAPVLPS RDNEIVDSAS VPETPLDCEV SLWSSWGLCG GHCGRLGTKS
   301  RTRYVRVQPA NNGSPCPELE EEAECVPDNC V

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SPON2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 186 nTPM

Expression across tissuesHPA

Tissue

cervix: 186 nTPM
endometrium: 184 nTPM
prostate: 127 nTPM
vagina: 107 nTPM
liver: 87 nTPM
adipose tissue: 72 nTPM

Single-cell type

decidual stromal cells: 928 nCPM
extravillous trophoblasts: 566 nCPM
nk-cells: 357 nCPM
thymocytes: 213 nCPM
endometrial stromal cells: 209 nCPM
hepatic stellate cells: 207 nCPM

Immune cell

gdT-cell: 257 nTPM
total PBMC: 124 nTPM
memory CD8 T-cell: 106 nTPM
naive CD8 T-cell: 97 nTPM
NK-cell: 51 nTPM
plasmacytoid DC: 43 nTPM

Brain region

cerebellum: 37 nTPM
basal ganglia: 21 nTPM
amygdala: 13 nTPM
hippocampal formation: 12 nTPM
choroid plexus: 12 nTPM
pons: 12 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.89
gnomAD pLI: 0
gnomAD missense Z: -0.81

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SPON2 as an antibody target. Whether an autoantibody or antibody against SPON2 could matter depends on whether native SPON2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SPON2 is annotated as secreted, so native SPON2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label SPON2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...